Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL

JERUSALEM, Jan. 7, 2026 /PRNewswire/ — Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI); (“Scinai”, or the “Company”), a biopharmaceutical company developing inflammation and immunology (I&I) therapeutics and operating a growing boutique CDMO business unit, today announced that its Chief Executive Officer, Amir Reichman, will co-lead a roundtable discussion organized by the Manufacturers Association of Israel during HealthIL Week 2026.

The roundtable, titled “Biopharma Manufacturing in Israel: Capabilities, Gaps, and Scale,” will take place on January 19, 2026 at Expo Tel Aviv. The session is a Manufacturers Association–led roundtable and will be jointly led by Mr.  Reichman together with senior representatives of the Manufacturers Association of Israel.

The roundtable was convened at the request of the Manufacturers Association to facilitate a realistic, fact-based discussion on Israel’s biopharma development and manufacturing ecosystem, with a particular focus on early-stage development, CMC activities, and clinical manufacturing across the full development continuum.

The discussion will emphasize early-stage development and clinical manufacturing, including access to laboratory infrastructure, CMC and analytical capabilities, and GMP manufacturing for clinical supply. These capabilities form the foundation for efficient development, regulatory readiness, and informed investment decisions.

Within this lifecycle view, the roundtable will examine readiness for later-stage and commercial manufacturing in Israel, the role of local and international CDMOs, and the current scope of manufacturing capabilities, structural gaps, and collaboration models across the ecosystem.

The discussion will further consider global trends shaping biopharma manufacturing, including the increasing complexity of biologic modalities and formats, evolving regulatory expectations, and the growing reliance on specialized CDMOs, and how national capabilities should evolve over the next 5–10 years to remain competitive.

“The Manufacturers Association plays a central role in shaping Israel’s industrial capabilities,” said Mr.  Reichman. “This roundtable is intended to examine, in a practical and grounded way, whether Israel has the development and manufacturing infrastructure needed to support biopharma companies from early clinical stages onward and what actions are required to strengthen that foundation.”

Participants are expected to include representatives from government and public agencies, Israeli and international biopharma manufacturers and CDMOs, multinational pharmaceutical companies, biotech companies with clinical and commercial experience, and investors with direct exposure to biopharma development and manufacturing risk.

HealthIL Week is Israel’s leading international conference for healthcare innovation, bringing together stakeholders from industry, academia, government, and the investment community to address challenges shaping the future of healthcare and life sciences.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company with two complementary business units:

• Scinai Bioservices, a boutique CDMO providing analytical method development, process development, and clinical cGMP manufacturing services for biotech clients worldwide.
• Scinai R&D, focused on developing innovative I&I therapeutics based on NanoAbs (VHH antibody fragments) with unique physicochemical properties suitable for advanced mono- and multi-specific antibody formats

Company website: www.scinai.com

Company Contacts

Investor Relations – Allele Capital Partners | +1 978 857 5075 | [email protected]
Business Development | +972 8 930 2529 | [email protected]

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements. These forward-looking statements reflect management’s current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics Ltd. Risks and uncertainties include, but are not limited to; the risk that the Company will otherwise be unable to remain compliant with the continued listing requirements of Nasdaq; lower than anticipated revenues of Scinai’s CDMO business in 2025 and thereafter, failure to sign agreements with other potential clients of the CDMO business; failure to receive grants under the EU STEP program or a delay in receiving grant decisions; delay in commencement of commercial operation of advanced sterile fill-and-finish system; a delay in the commencement and results of pre-clinical and clinical studies, the risk of delay in, Scinai’s inability to conduct, or the unsuccessful results of, its research and development activities, including the contemplated in-vivo studies and a clinical trial; the risk that Scinai will not be successful in expanding its CDMO business or in-license other NanoAbs; the risk that Scinai may not be able to secure additional capital on attractive terms, if at all; the risk that the therapeutic and commercial potential of NanoAbs will not be met or that Scinai will not be successful in bringing the NanoAbs towards commercialization; the risk of a delay in the preclinical and clinical trials data for NanoAbs, if any; the risk that our business strategy may not be successful; Scinai’s ability to acquire rights to additional product opportunities; Scinai’s ability to enter into collaborations on terms acceptable to Scinai or at all; timing of receipt of regulatory approval of Scinai’s manufacturing facility in Jerusalem, if at all or when required; the risk that the manufacturing facility will not be able to be used for a wide variety of applications and other vaccine and treatment technologies; and the risk that drug development involves a lengthy and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s Annual Report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on May 7, 2025, and the Company’s subsequent filings with the SEC. Scinai undertakes no obligation to revise or update any forward-looking statement for any reason.

Logo – https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/scinai-ceo-amir-reichman-to-co-lead-manufacturers-association-biopharma-manufacturing-roundtable-at-healthil-302655108.html

SOURCE Scinai Immunotherapeutics Ltd.